Methods and means for the production of Ig-like molecules
The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.
1. A heterodimeric antibody comprising a first human CH3 domain comprising a positively charged amino acid residue at position 364 according to the EU numbering system, and a second human CH3 domain comprising a negatively charged amino acid residue at position 368 according to the EU numbering system.
2. The heterodimeric antibody of claim 1 , wherein said positively charged amino acid residue at position 364 comprises a lysine (K) or an arginine (R) residue, and wherein said negatively charged residue at position 368 comprises an aspartic acid (D) or glutamic acid (E) residue.
3. The heterodimeric antibody of claim 2 , wherein said positively charged amino acid residue at position 364 comprises a lysine (K) residue, and wherein said negatively charged amino acid residue at position 368 comprises an aspartic acid (D).
4. The heterodimeric antibody of claim 1 , wherein said heterodimeric antibody is a bispecific antibody.
5. The heterodimeric antibody of claim 1 , wherein said heterodimeric antibody is human IgG.
6. The heterodimeric antibody of claim 1 , wherein said heterodimeric antibody is human IgG1.
7. A pharmaceutical composition comprising the heterodimeric antibody according to claim 1 , and a pharmaceutically acceptable carrier.